CERS earnings: next report 2026-07-30, real EPS beat/miss history, analyst consensus Buy, P/E -58.87. Updated 2026-07-23.
Cerus (CERS) Research Hub
Cerus (CERS) trades on NASDAQ, US in the Healthcare (Medical - Devices) sector. As of 2026-09-11, shares last closed at 2.49 USD (-0.80%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -58.87, market cap 0.63B. This hub links to the full technical, earnings and options research available for CERS.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Medical - Devices) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 2.49 USD (-0.80%) |
| 52-week range | 2.06 USD – 3.47 USD |
| Trend regime | Range |
| 14-day RSI | 55.9 (Bullish) |
| Trailing P/E | -58.87 |
| Market cap | 0.63B |
| Dividend yield | 0.00% |
| Next earnings | 2026-07-30 |
Available research for CERS
Covered Call on CERS: how it works, illustrative setup around the real 2.49 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on CERS: how it works, illustrative setup around the real 2.49 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on CERS: how it works, illustrative setup around the real 2.49 USD price, max profit/loss, breakeven and when to use it. Educational.
CERS technical analysis: range, last 2.49 USD, RSI 55.9, 52w range 2.06 USD–3.47 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is CERS in?
Cerus (CERS) is classified under Healthcare (Medical - Devices), listed on NASDAQ, US.
Is CERS in an uptrend or downtrend?
As of 2026-09-11, CERS is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is CERS's trailing P/E ratio?
CERS's trailing P/E is -58.87, with a market cap of 0.63B. See the earnings research page for full valuation detail.
When does CERS next report earnings?
CERS is next scheduled to report earnings on 2026-07-30, with a consensus EPS estimate of -0.01333 USD.